Relmada Therapeutics
RLMD
#8408
Rank
โ‚ฌ0.25 B
Marketcap
2,39ย โ‚ฌ
Share price
-15.76%
Change (1 day)
-35.58%
Change (1 year)

EPS for Relmada Therapeutics (RLMD)

EPS in 2026 (TTM): -0,80ย โ‚ฌ

According to Relmada Therapeutics's latest financial reports the company's current EPS (TTM) is -0,85ย โ‚ฌ. In 2025 the company made an earnings per share (EPS) of -1,32ย โ‚ฌ an increase over its 2024 EPS that were of -2,42ย โ‚ฌ.

EPS history for Relmada Therapeutics from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)-0,80ย โ‚ฌ-39.73%
2025-1,32ย โ‚ฌ-45.28%
2024-2,42ย โ‚ฌ-19.21%
2023-2,99ย โ‚ฌ-38.11%
2022-4,83ย โ‚ฌ-25.98%
2021-6,53ย โ‚ฌ87.93%
2020-3,47ย โ‚ฌ39.05%
2019-2,50ย โ‚ฌ-4.2%
2018-2,61ย โ‚ฌ37.5%
2017-1,90ย โ‚ฌ100%
2016-0,95ย โ‚ฌ-87.56%
2015-7,62ย โ‚ฌ
2013-0,02880ย โ‚ฌ273.48%
2012-0,007710ย โ‚ฌ

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Cytokinetics
CYTK
-5,51ย โ‚ฌ 549.46%๐Ÿ‡บ๐Ÿ‡ธ USA
Taro Pharmaceutical
TARO
1,11ย โ‚ฌ-231.18%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel